Qisda Corporation has identified its medical business as its primary growth driver. The division reported double-digit year-on-year growth for the first three quarters of 2025, with management targeting continued double-digit growth next year.

Strategic Business Pillars:

• Regenerative Medicine: Qisda’s strategic investment in Ascendo Biotech (陞醫生技) focuses on exosome products using "Bio-Pulsed" technology for high purity and shelf stability. Qisda plans to move Ascendo toward an Emerging Stock Board listing to capture the anti-aging and hair regrowth consumer markets.
• Medical Imaging: In collaboration with AUO, the company has mass-produced the QMUT ultrasound probe using a panel-based printing process that yields thousands of units per substrate, enhancing resolution and cost-efficiency.
• Digital Health: DKABio (浚鴻數據) has launched a "Digital Twin for Health" system, using AI to predict personal health risks.
• Dialysis: BenQ Medical Technology is expanding its dialysis capacity and yield, with the dialysis business expected to be a core growth driver in 2026.

Resource: 佳世達聚焦醫療事業，明年營收拚雙位數成長